Detalhe da pesquisa
1.
Therapeutic Drug Monitoring of Orally Administered Letermovir Prophylaxis in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
Antimicrob Agents Chemother
; 66(8): e0065722, 2022 08 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-35876579
2.
Predictors of breakthrough clinically significant cytomegalovirus infection during letermovir prophylaxis in high-risk hematopoietic cell transplant recipients.
Immun Inflamm Dis
; 9(3): 771-776, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-33949798
3.
Letermovir Primary Prophylaxis in High-Risk Hematopoietic Cell Transplant Recipients: A Matched Cohort Study.
Vaccines (Basel)
; 9(4)2021 Apr 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33921218